NEW YORK, United States – The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday. It now “anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus…Read More
Pfizer cuts earnings outlook on lower Covid19 drug sales
